Organization | People's Hospital of Zhongshan

People's Hospital of Zhongshan Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2006

NCT00744302

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

Department of Nephrology, People's Hospital of Zhongshan City | People's Hospital of Zhongshan | People's Hospital of Zhongshan City | Tianshu Liu

Active Ingredients

Drugs in Phase 3 Trials (2)

cisplatin (platinol) (1 trial)

ulinastatin (1 trial)

Drugs in Phase 2 Trials (11)

calcium (1 trial)

capecitabine (xeloda) (1 trial)

cetuximab (erbitux) (1 trial)

docetaxel (taxotere) (1 trial)

fluorouracil (efudex) (1 trial)

gimeracil (1 trial)

irinotecan (Camptosar) (1 trial)

oteracil (1 trial)

oxaliplatin (eloxatin) (1 trial)

tegafur (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 3)

Colorectal Neoplasms (Phase 2)

Hypercalcemia (Phase 2)

Hyperparathyroidism (Phase 2)

Mucositis (Phase 3)

Nasopharyngeal Carcinoma (Phase 3)

Stomach Neoplasms (Phase 2)

Stomatitis (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial APIs: 13